The EPS miss and accelerating cash burn are near-term negatives for a pre-revenue biotech, but the stock's reaction will hinge on the pipeline narrative. The key catalysts are the D2T RA and CLE data readouts in H2 2026 — positive results could quickly reverse the bearish sentiment. Monitor cash runway closely; at the current burn rate, the $797.8M provides approximately 5-6 quarters of runway, which aligns with the stated goal of funding to a potential GD launch.
Price Chart
Executive Summary
Immunovant reported a Q1 FY2027 net loss of $153.2M ($-0.75/share), which was a 22.2% miss vs the $-0.61 consensus estimate. The wider loss was driven by increased R&D spending on IMVT-1402 clinical trials. Cash burn reduced the balance to $797.8M from $902.1M at March 31, 2026. All pipeline timelines remain on track with key data readouts expected in H2 2026 (D2T RA, CLE) and 2027 (GD, MG). The EPS miss is notable for a pre-revenue biotech, but the pipeline narrative remains intact.
Key Financial Metrics
Key Facts
- Net loss of $153.2M ($-0.75/share) for Q1 ended June 30, 2026, vs consensus $-0.61 (22.2% miss)
- Cash and equivalents fell to $797.8M from $902.1M at March 31, 2026, a burn of ~$104M in the quarter
- R&D expenses rose to $142.6M from $101.2M YoY, driven by IMVT-1402 clinical activities and contract manufacturing
- All six IMVT-1402 programs remain on track: D2T RA and CLE data in H2 2026; GD and MG data in 2027; CIDP and SjD data in 2028
- Cash runway provides funding to potential commercial launch of IMVT-1402 in Graves disease
Financial Impact
Net loss of $153.2M was $32.6M wider than the $120.6M loss in the year-ago quarter, and $32.6M worse than consensus
Risk Factors
- Clinical trial failure for IMVT-1402 in any of the six indications
- Faster-than-expected cash burn requiring dilutive financing before data readouts
- Negative topline data from D2T RA or CLE trials in H2 2026 could significantly impair the pipeline thesis
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001764013-26-000100 |
| Document: imvt-20260806.htm | 0001764013-26-000100 |
| Document: 0001764013-26-000100-index-headers.html | 0001764013-26-000100 |
| Document: 0001764013-26-000100-index.html | 0001764013-26-000100 |
| Document: 0001764013-26-000100.txt | 0001764013-26-000100 |
| 8-K Data (Synthetic) | 0001764013-26-000100 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $39.74 $39.12 | ▲ +1.56% | ▲ +2.16% | $27.68 (+30.35%) |
Jul 24, 2026 13w ago | Insider Cluster | $40.09 $43.32 | ▲ +8.06% | ▲ +4.76% | $27.68 (−30.96%) |
Jun 26, 2026 17w ago | Insider Cluster | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 26, 2026 17w ago | Insider Cluster | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 26, 2026 17w ago | 144 | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 26, 2026 17w ago | 144 | $38.51 $39.41 | ▲ +2.34% | ▲ +2.62% | $27.68 (−28.12%) |
Jun 15, 2026 18w ago | 144 | $33.61 $38.77 | ▲ +15.35% | ▲ +15.15% | $27.68 (−17.64%) |
May 28, 2026 21w ago | 144 | $33.30 $38.51 | ▲ +15.65% | ▲ +17.44% | $27.68 (−16.88%) |
May 20, 2026 22w ago | 8-K | $35.56 $35.34 | ▼ −0.62% | ▼ −1.36% | $27.68 (−22.16%) |
May 20, 2026 22w ago | Press Release | $35.56 $35.34 | ▼ −0.62% | ▼ −1.36% | $27.68 (−22.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers